CHDD
CHDD popup menu
 
chdd logo
Center on Human Development and Disability
About CHDD | IDDRC | UCEDD   

CHDD is located on the Lake Washington Ship Canal

Home Page

Collaborative
Research Areas


Research Affiliates

Core Services

Animal
Behavior
Core


Brain
Imaging
Core


Clinical
Translational
Core


Genetics
Core

Sandra Juul, M.D., Ph.D.

Professor of Pediatrics
Research Affiliate, Center on Human Development and Disability
sjuul@uw.edu
206-221-6814
University of Washington
Box 356320
Seattle, WA 98195-6320

Sandra Juul

Dr. Juul leads a translational neonatal neuroscience research program. The focus is to identify new therapeutic approaches to neonatal brain injury, determine whether they are safe and effective, and if so, bring these new treatments from the laboratory to the bedside.

Dr. Juul identified Epo and its receptor in the developing human brain, demonstrated that it is neuroprotective and safe using multiple animal models of neonatal brain injury. Bringing this work from the bench to the bedside, Dr. Juul is currently Principal Investigator of a multicenter randomized controlled trial to determine whether Epo is a safe and effective neuroprotectant for extremely preterm infants. The study, Preterm Epo Neuroprotection (PENUT) is funded by NINDS, and has enrolled 940 babies born between 24-0/7 and 26-6/7 weeks of gestation. These children are currently being followed to two years of age for detailed neurodevelopmental assessments.

Dr. Juul is also multi-PI with Dr. Yvonne Wu (UCSF) on the High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) Trial, a randomized controlled trial of Epo neuroprotection for 500 term infants with hypoxic-ischemic encephalopathy (HIE). This multicenter trial will determine whether Epo in addition to therapeutic cooling will improve the outcome for infants with HIE.


University of Washington • Center on Human Development and Disability • Box 357920 • Seattle WA 98195-7920 USA • 206-543-7701 • chdd@uw.edu